Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

2.76USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$2.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,007,738
52-wk High
$6.96
52-wk Low
$0.67

Chart for

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $317.05
Shares Outstanding(Mil.): 114.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES​ Source text for Eikon: Further company coverage:

Feb 06 2018

BRIEF-Mannkind, On Jan 18, Co, Unit Entered Into Exchange, Sixth Amendment To Facility Agreement With Deerfield

* MANNKIND - ‍ ON JAN 18, CO AND UNIT ENTERED INTO AN EXCHANGE AND SIXTH AMENDMENT TO FACILITY AGREEMENT WITH DEERFIELD - SEC FILING​

Jan 19 2018

BRIEF-Mannkind Q3 loss per share $0.31

* Mannkind Corporation reports 2017 third quarter financial results

Nov 07 2017

BRIEF-Mannkind restructures near-term debt obligations

* Mannkind Corp - ‍extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock​

Oct 23 2017

BRIEF-Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

* Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

Oct 23 2017

Competitors

Earnings vs. Estimates